Endostatin is a naturally occurring anti-angiogenic protein derived from collagen XVIII that inhibits new blood vessel formation. This 20 kDa C-terminal fragment plays a crucial role in regulating angiogenesis, making it a potential therapeutic target for cancer and other angiogenesis-dependent diseases. The protein exists in two primary forms: natural Endostatin extracted from human tissues and recombinant Endostatin produced through genetic engineering techniques.
The market growth is primarily driven by increasing cancer research activities and rising demand for angiogenesis inhibitors. However, challenges such as high production costs and complex purification processes may restrain market expansion. Recent developments include enhanced recombinant expression systems and improved stabilization techniques, with key players like Sigma-Aldrich and R&D Systems introducing high-purity Endostatin variants for research applications.
Get the Complete Report & TOC at https://www.intelmarketresearch.com/pharmaceuticals/5749/endostatin-protein-2025-2032-955